CoChat
Sign Up
Cited by 105NF-κB Signaling PathwaysLymphoma Diagnosis and TreatmentSignaling Pathways in Disease

NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms

Open access
Yu, Li, Li, Ling, Medeiros, L. Jeffrey, Young, Ken H.·2017·Blood Reviews
DOI 10.1016/j.blre.2016.10.001PMC PMC5382109
Open this paper in CoChat — free account

Abstract

The NF-κB pathway, a critical regulator of apoptosis, plays a key role in many normal cellular functions. Genetic alterations and other mechanisms leading to constitutive activation of the NF-κB pathway contribute to cancer development, progression and therapy resistance by activation of downstream anti-apoptotic pathways, unfavorable microenvironment interactions, and gene dysregulation. Not surprisingly, given its importance to normal and cancer cell function, the NF-κB pathway has emerged as a target for therapy. In the review, we present the physiologic role of the NF-κB pathway and recent advances in better understanding of the pathologic roles of the NF-κB pathway in major types of lymphoid neoplasms. We also provide an update of clinical trials that use NF-κB pathway inhibitors. These trials are exploring the clinical efficiency of combining NF-κB pathway inhibitors with various agents that target diverse mechanisms of action with the goal being to optimize novel therapeutic opportunities for targeting oncogenic pathways to eradicate cancer cells.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.blre.2016.10.001

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Aberrant activation of NF-κB signaling is crucial in MM pathogenesis.

    “The aberrant activation of NF-κB signaling is crucial in MM pathogenesis.”

    From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [60]

    The Introduction states that constitutive NF-κB activation promotes malignant cell survival and proliferation, and Section 5 links NF-κB pathway activation to oncogenesis in B-cell lymphomas. Those passages support the pathway’s pathogenic importance in lymphomas, but the passages retrieved for “multiple myeloma” and “MM” do not establish its role specifically in MM pathogenesis. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

  • Approximately 80% of MM patients exhibit elevated levels of NF-κB p65 subunits in bone marrow samples.

    “Approximately 80% of MM patients exhibit elevated levels of NF-κB p65 subunits in bone marrow samples [60, 61, 138, 139].”

    From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [60]

    Section 7 discusses NF-κB activity in bone marrow cells from chronic lymphocytic leukemia, not multiple myeloma (MM). Searches for MM, p65 in bone marrow samples, and 80% found no passage reporting the claimed prevalence in MM patients. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 163

  1. [1]Burger JA Ghia P Rosenwald A Caligaris-Cappio F The microenvironment in mature B-cell malignancies: a target for new treatment strategies Blood 2009 114 3367 3375 19636060 PMC4969052
  2. [2]Davis RE Ngo VN Lenz G Tolar P Young RM Romesser PB Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 2010 463 88 92 20054396 PMC2845535
  3. [3]Scott DW Gascoyne RD The tumour microenvironment in B cell lymphomas Nat Rev Cancer 2014 14 517 534 25008267
  4. [4]Gires O Zimber-Strobl U Gonnella R Ueffing M Marschall G Zeidler R Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule EMBO J 1997 16 6131 6140 9359753 PMC1326297
  5. [5]Thorley-Lawson DA Allday MJ The curious case of the tumour virus: 50 years of Burkitt's lymphoma Nat Rev Microbiol 2008 6 913 924 19008891
  6. [6]Maes B Demunter A Peeters B De Wolf-Peeters C BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression Blood 2002 99 1398 1404 11830492
  7. [8]Zhang Q Siebert R Yan M Hinzmann B Cui X Xue L Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32) Nat Genet 1999 22 63 68 10319863
  8. [9]Kim SW Ramasamy K Bouamar H Lin AP Jiang D Aguiar RC MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) Proc Natl Acad Sci U S A 2012 109 7865 7870 22550173 PMC3356650
  9. [10]Ben-Neriah Y Karin M Inflammation meets cancer, with NF-kappaB as the matchmaker Nat Immunol 2011 12 715 723 21772280
  10. [11]Huang DB Vu D Ghosh G NF-kappaB RelB forms an intertwined homodimer Structure 2005 13 1365 1373 16154093
  11. [12]Hinz M Arslan SC Scheidereit C It takes two to tango: IkappaBs, the multifunctional partners of NF-kappaB Immunol Rev 2012 246 59 76 22435547
  12. [13]Liu F Xia Y Parker AS Verma IM IKK biology Immunol Rev 2012 246 239 253 22435559 PMC3311052
  13. [14]Kanarek N Ben-Neriah Y Regulation of NF-kappaB by ubiquitination and degradation of the IkappaBs Immunol Rev 2012 246 77 94 22435548
  14. [15]Baldwin AS Regulation of cell death and autophagy by IKK and NF-kappaB: critical mechanisms in immune function and cancer Immunol Rev 2012 246 327 345 22435564
  15. [16]Pomerantz JL Baltimore D Two pathways to NF-kappaB Mol Cell 2002 10 693 695 12419209
  16. [17]Bonizzi G Karin M The two NF-kappaB activation pathways and their role in innate and adaptive immunity Trends Immunol 2004 25 280 288 15145317
  17. [18]Jimi E Phillips RJ Rincon M Voll R Karasuyama H Flavell R Activation of NF-kappaB promotes the transition of large, CD43+ pre-B cells to small, CD43- pre-B cells Int Immunol 2005 17 815 825 15908447
  18. [19]Derudder E Cadera EJ Vahl JC Wang J Fox CJ Zha S Development of immunoglobulin lambda-chain-positive B cells, but not editing of immunoglobulin kappa-chain, depends on NF-kappaB signals Nat Immunol 2009 10 647 654 19412180 PMC2742984
  19. [20]Castro I Wright JA Damdinsuren B Hoek KL Carlesso G Shinners NP B cell receptor-mediated sustained c-Rel activation facilitates late transitional B cell survival through control of B cell activating factor receptor and NF-kappaB2 J Immunol 2009 182 7729 7737 19494297 PMC2770265
  20. [21]Smith SH Cancro MP Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors J Immunol 2003 170 5820 5823 12794106
  21. [22]Mora AL Stanley S Armistead W Chan AC Boothby M Inefficient ZAP-70 phosphorylation and decreased thymic selection in vivo result from inhibition of NF-kappaB/Rel J Immunol 2001 167 5628 5635 11698434
  22. [23]Oh H Ghosh S NF-kappaB: roles and regulation in different CD4(+) T-cell subsets Immunol Rev 2013 252 41 51 23405894 PMC3576882
  23. [25]Gerondakis S Banerjee A Grigoriadis G Vasanthakumar A Gugasyan R Sidwell T NF-kappaB subunit specificity in hemopoiesis Immunol Rev 2012 246 272 285 22435561
  24. [26]Gasparini C Celeghini C Monasta L Zauli G NF-kappaB pathways in hematological malignancies Cell Mol Life Sci 2014 71 2083 2102 24419302 PMC11113378
  25. [27]Mohamed AJ Yu L Backesjo CM Vargas L Faryal R Aints A Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain Immunol Rev 2009 228 58 73 19290921
  26. [28]Eliopoulos AG Caamano JH Flavell J Reynolds GM Murray PG Poyet JL Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway Oncogene 2003 22 7557 7569 14576817
  27. [29]Broemer M Krappmann D Scheidereit C Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation Oncogene 2004 23 5378 5386 15077173
  28. [30]Walter HS Rule SA Dyer MJ Karlin L Jones C Cazin B A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies Blood 2016 127 411 419 26542378 PMC4731845
  29. [31]Niemann CU Wiestner A B-cell receptor signaling as a driver of lymphoma development and evolution Semin Cancer Biol 2013 23 410 421 24060900 PMC4208312
  30. [32]Saijo K Mecklenbrauker I Santana A Leitger M Schmedt C Tarakhovsky A Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha J Exp Med 2002 195 1647 1652 12070292 PMC2193563
  31. [33]Holler C Pinon JD Denk U Heyder C Hofbauer S Greil R PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia Blood 2009 113 2791 2794 19168795
  32. [34]Lutzny G Kocher T Schmidt-Supprian M Rudelius M Klein-Hitpass L Finch AJ Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo Cancer Cell 2013 23 77 92 23328482 PMC3546417
  33. [35]Kim SW Oleksyn DW Rossi RM Jordan CT Sanz I Chen L Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells Blood 2008 111 1644 1653 18025152
  34. [36]Naylor TL Tang H Ratsch BA Enns A Loo A Chen L Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas Cancer Res 2011 71 2643 2653 21324920
  35. [37]Beckwith M Jorgensen G Longo DL The protein product of the proto-oncogene c-cbl forms a complex with phosphatidylinositol 3-kinase p85 and CD19 in anti-IgM-stimulated human B-lymphoma cells Blood 1996 88 3502 3507 8896416
  36. [38]Inabe K Kurosaki T Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement Blood 2002 99 584 589 11781242
  37. [39]Herman SE Johnson AJ Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia Clin Cancer Res 2012 18 4013 4018 22711705 PMC3425377
  38. [40]Manning BD Cantley LC AKT/PKB signaling: navigating downstream Cell 2007 129 1261 1274 17604717 PMC2756685
  39. [41]Baracho GV Miletic AV Omori SA Cato MH Rickert RC Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation Curr Opin Immunol 2011 23 178 183 21277760 PMC3070849
  40. [42]Srinivasan L Sasaki Y Calado DP Zhang B Paik JH DePinho RA PI3 kinase signals BCR-dependent mature B cell survival Cell 2009 139 573 586 19879843 PMC2787092
  41. [43]Jellusova J Miletic AV Cato MH Lin WW Hu Y Bishop GA Context-specific BAFF-R signaling by the NF-kappaB and PI3K pathways Cell Rep 2013 5 1022 1035 24239354 PMC3887557
  42. [44]Kloo B Nagel D Pfeifer M Grau M Duwel M Vincendeau M Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells Proc Natl Acad Sci U S A 2011 108 272 277 21173233 PMC3017191
  43. [45]Chen L Monti S Juszczynski P Ouyang J Chapuy B Neuberg D SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas Cancer Cell 2013 23 826 838 23764004 PMC3700321
  44. [46]Ghosh S Gifford AM Riviere LR Tempst P Nolan GP Baltimore D Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal Cell 1990 62 1019 1029 2203532
  45. [47]Kieran M Blank V Logeat F Vandekerckhove J Lottspeich F Le Bail O The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product Cell 1990 62 1007 1018 2203531
  46. [48]Bargou RC Leng C Krappmann D Emmerich F Mapara MY Bommert K High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells Blood 1996 87 4340 4347 8639794
  47. [49]Emmerich F Meiser M Hummel M Demel G Foss HD Jundt F Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells Blood 1999 94 3129 3134 10556199
  48. [50]Cabannes E Khan G Aillet F Jarrett RF Hay RT Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha Oncogene 1999 18 3063 3070 10340377
  49. [51]Jungnickel B Staratschek-Jox A Brauninger A Spieker T Wolf J Diehl V Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma J Exp Med 2000 191 395 402 10637284 PMC2195754
  50. [52]Lenz G Davis RE Ngo VN Lam L George TC Wright GW Oncogenic CARD11 mutations in human diffuse large B cell lymphoma Science 2008 319 1676 1679 18323416
  51. [53]Compagno M Lim WK Grunn A Nandula SV Brahmachary M Shen Q Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma Nature 2009 459 717 721 19412164 PMC2973325
  52. [54]Liu H Ruskon-Fourmestraux A Lavergne-Slove A Ye H Molina T Bouhnik Y Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy Lancet 2001 357 39 40 11197361
  53. [55]Lin SC Lo YC Wu H Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling Nature 2010 465 885 890 20485341 PMC2888693
  54. [56]Ngo VN Young RM Schmitz R Jhavar S Xiao W Lim KH Oncogenically active MYD88 mutations in human lymphoma Nature 2011 470 115 119 21179087 PMC5024568
  55. [57]Young RM Staudt LM Targeting pathological B cell receptor signalling in lymphoid malignancies Nat Rev Drug Discov 2013 12 229 243 23449308 PMC7595252
  56. [58]Lenz G Nagel I Siebert R Roschke AV Sanger W Wright GW Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma J Exp Med 2007 204 633 643 17353367 PMC2137913
  57. [59]Staudt LM A closer look at follicular lymphoma N Engl J Med 2007 356 741 742 17301308
  58. [60]Vaandrager JW Schuuring E Kluin-Nelemans HC Dyer MJ Raap AK Kluin PM DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma Blood 1998 92 2871 2878 9763572
  59. [61]Johnson RF Perkins ND Nuclear factor-kappaB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect Trends Biochem Sci 2012 37 317 324 22626470
  60. [62]Tergaonkar V Pando M Vafa O Wahl G Verma I p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy Cancer Cell 2002 1 493 503 12124178
  61. [64]Huang WC Ju TK Hung MC Chen CC Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB Mol Cell 2007 26 75 87 17434128 PMC2312502
  62. [65]Schumm K Rocha S Caamano J Perkins ND Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit EMBO J 2006 25 4820 4832 16990795 PMC1618099
  63. [66]Roberts AW Seymour JF Brown JR Wierda WG Kipps TJ Khaw SL Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease J Clin Oncol 2012 30 488 496 22184378 PMC4979082
  64. [67]van Keimpema M Gruneberg LJ Mokry M van Boxtel R Koster J Coffer PJ FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-kappaB to promote survival of human B cells Blood 2014 124 3431 3440 25267198 PMC4246697
  65. [68]Stoffel A Chaurushiya M Singh B Levine AJ Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis Proc Natl Acad Sci U S A 2004 101 9079 9084 15184680 PMC428476
  66. [69]Ramachandiran S Adon A Guo X Wang Y Wang H Chen Z Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-kappaB pathway Int J Cancer 2015 136 2341 2351 25359525 PMC4880031
  67. [70]Musilova K Mraz M MicroRNAs in B-cell lymphomas: how a complex biology gets more complex Leukemia 2015 29 1004 1017 25541152
  68. [71]Jeong D Kim J Nam J Sun H Lee YH Lee TJ MicroRNA-124 links p53 to the NF-kappaB pathway in B-cell lymphomas Leukemia 2015 29 1868 1874 25915824
  69. [72]Mathas S Hinz M Anagnostopoulos I Krappmann D Lietz A Jundt F Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B EMBO J 2002 21 4104 4113 12145210 PMC126136
  70. [73]Xu J Zhou P Wang W Sun A Guo F RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow J Mol Med (Berl) 2014 92 77 92 24042463
  71. [74]Lwin T Hazlehurst LA Li Z Dessureault S Sotomayor E Moscinski LC Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells Leukemia 2007 21 1521 1531 17476277
  72. [75]Gregoire M Guilloton F Pangault C Mourcin F Sok P Latour M Neutrophils trigger a NF-kappaB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas Oncotarget 2015 6 16471 16487 26158216 PMC4599283
  73. [76]Kim YR Eom KS Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial Effect in Overcoming Stroma-Mediated Chemotherapy Resistance in Mantle Cell Lymphoma Cells Immune Netw 2014 14 296 306 25550696 PMC4275387
  74. [77]Coscia M Pantaleoni F Riganti C Vitale C Rigoni M Peola S IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells Leukemia 2011 25 828 837 21372840
  75. [78]O'Sullivan BJ MacDonald KP Pettit AR Thomas R RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function Proc Natl Acad Sci U S A 2000 97 11421 11426 11027342 PMC17215
  76. [79]Boll B Eltaib F Reiners KS von Tresckow B Tawadros S Simhadri VR Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity Clin Cancer Res 2009 15 5108 5116 19671844
  77. [80]Bartel DP MicroRNAs: target recognition and regulatory functions Cell 2009 136 215 233 19167326 PMC3794896
  78. [81]Zhou B Wang S Mayr C Bartel DP Lodish HF miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely Proc Natl Acad Sci U S A 2007 104 7080 7085 17438277 PMC1855395
  79. [82]Lawrie CH Soneji S Marafioti T Cooper CD Palazzo S Paterson JC MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma Int J Cancer 2007 121 1156 1161 17487835
  80. [83]Zhao JJ Lin J Lwin T Yang H Guo J Kong W microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma Blood 2010 115 2630 2639 20086245 PMC2852365
  81. [84]Eis PS Tam W Sun L Chadburn A Li Z Gomez MF Accumulation of miR-155 and BIC RNA in human B cell lymphomas Proc Natl Acad Sci U S A 2005 102 3627 3632 15738415 PMC552785
  82. [85]Roehle A Hoefig KP Repsilber D Thorns C Ziepert M Wesche KO MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas Br J Haematol 2008 142 732 744 18537969
  83. [86]Vargova K Curik N Burda P Basova P Kulvait V Pospisil V MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia Blood 2011 117 3816 3825 21296997
  84. [87]Malumbres R Sarosiek KA Cubedo E Ruiz JW Jiang X Gascoyne RD Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas Blood 2009 113 3754 3764 19047678 PMC2670792
  85. [88]Costinean S Zanesi N Pekarsky Y Tili E Volinia S Heerema N Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice Proc Natl Acad Sci U S A 2006 103 7024 7029 16641092 PMC1459012
  86. [89]Costinean S Sandhu SK Pedersen IM Tili E Trotta R Perrotti D Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice Blood 2009 114 1374 1382 19520806 PMC2727407
  87. [90]Thompson RC Herscovitch M Zhao I Ford TJ Gilmore TD NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway J Biol Chem 2011 286 1675 1682 20947507 PMC3023462
  88. [91]Thompson RC Vardinogiannis I Gilmore TD Identification of an NF-kappaB p50/p65-responsive site in the human MIR155HG promoter BMC Mol Biol 2013 14 24 24059932 PMC3849010
  89. [92]Gatto G Rossi A Rossi D Kroening S Bonatti S Mallardo M Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway Nucleic Acids Res 2008 36 6608 6619 18940871 PMC2582607
  90. [93]Motsch N Pfuhl T Mrazek J Barth S Grasser FA Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a RNA Biol 2007 4 131 137 18347435
  91. [95]Contreras JR Palanichamy JK Tran TM Fernando TR Rodriguez-Malave NI Goswami N MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1 Oncotarget 2015 6 11023 11037 25906746 PMC4484436
  92. [96]Arribas AJ Campos-Martin Y Gomez-Abad C Algara P Sanchez-Beato M Rodriguez-Pinilla MS Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets Blood 2012 119 e9 e21 22110251
  93. [97]Puente XS Pinyol M Quesada V Conde L Ordonez GR Villamor N Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia Nature 2011 475 101 105 21642962 PMC3322590
  94. [98]Mansouri L Sutton LA Ljungstrom V Bondza S Arngarden L Bhoi S Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia J Exp Med 2015 212 833 843 25987724 PMC4451125
  95. [99]Tuveson D Rai KR Augmenting NF-kappaB in poor-risk CLL: A general paradigm for other cancers? J Exp Med 2015 212 830 831 26034117 PMC4451126
  96. [100]Iannetti A Ledoux AC Tudhope SJ Sellier H Zhao B Mowla S Regulation of p53 and Rb links the alternative NF-kappaB pathway to EZH2 expression and cell senescence PLoS Genet 2014 10 e1004642 25255445 PMC4177746
  97. [101]Zanesi N Balatti V Riordan J Burch A Rizzotto L Palamarchuk A A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model Blood 2013 121 4355 4358 23591791 PMC3663428
  98. [102]Willis TG Jadayel DM Du MQ Peng H Perry AR Abdul-Rauf M Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types Cell 1999 96 35 45 9989495
  99. [103]Akagi T Motegi M Tamura A Suzuki R Hosokawa Y Suzuki H A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue Oncogene 1999 18 5785 5794 10523859
  100. [104]McAllister-Lucas LM Baens M Lucas PC MALT1 protease: a new therapeutic target in B lymphoma and beyond? Clin Cancer Res 2011 17 6623 6631 21868762 PMC3207008
  101. [105]Rosebeck S Madden L Jin X Gu S Apel IJ Appert A Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation Science 2011 331 468 472 21273489 PMC3124150
  102. [106]Pillai S Cariappa A The follicular versus marginal zone B lymphocyte cell fate decision Nat Rev Immunol 2009 9 767 777 19855403
  103. [107]Clipson A Wang M de Leval L Ashton-Key M Wotherspoon A Vassiliou G KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype Leukemia 2015 29 1177 1185 25428260
  104. [108]Parry M Rose-Zerilli MJ Ljungstrom V Gibson J Wang J Walewska R Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing Clin Cancer Res 2015 21 4174 4183 25779943 PMC4490180
  105. [109]Spina V Rossi D NF-kappaB deregulation in splenic marginal zone lymphoma Semin Cancer Biol 2016 10.1016/j.semcancer.2016.08.002 27503810 · DOI
  106. [110]Yan Q Huang Y Watkins AJ Kocialkowski S Zeng N Hamoudi RA BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas Haematologica 2012 97 595 598 22102703 PMC3347666
  107. [111]Rossi D Deaglio S Dominguez-Sola D Rasi S Vaisitti T Agostinelli C Alteration of BIRC3 and multiple other NF-kappa B pathway genes in splenic marginal zone lymphoma Blood 2011 118 4930 4934 21881048
  108. [112]Davis RE Brown KD Siebenlist U Staudt LM Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells J Exp Med 2001 194 1861 1874 11748286 PMC2193582
  109. [113]Rosenwald A Wright G Chan WC Connors JM Campo E Fisher RI The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 2002 346 1937 1947 12075054
  110. [114]Nogai H Wenzel SS Hailfinger S Grau M Kaergel E Seitz V IkappaB-zeta controls the constitutive NF-kappaB target gene network and survival of ABC DLBCL Blood 2013 122 2242 2250 23869088
  111. [115]Ya ng J Liao X Agarwal MK Barnes L Auron PE Stark GR Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB Genes Dev 2007 21 1396 1408 17510282 PMC1877751
  112. [116]Lam LT Wright G Davis RE Lenz G Farinha P Dang L Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma Blood 2008 111 3701 3713 18160665 PMC2275028
  113. [117]Klein U Casola S Cattoretti G Shen Q Lia M Mo T Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination Nat Immunol 2006 7 773 782 16767092
  114. [118]Mandelbaum J Bhagat G Tang H Mo T Brahmachary M Shen Q BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma Cancer Cell 2010 18 568 579 21156281 PMC3030476
  115. [119]Tam W Gomez M Chadburn A Lee JW Chan WC Knowles DM Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas Blood 2006 107 4090 4100 16424392
  116. [120]Schmidlin H Diehl SA Nagasawa M Scheeren FA Schotte R Uittenbogaart CH Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression Blood 2008 112 1804 1812 18552212 PMC2518887
  117. [121]Calado DP Zhang B Srinivasan L Sasaki Y Seagal J Unitt C Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma Cancer Cell 2010 18 580 589 21156282 PMC3018685
  118. [122]Li L Xu-Monette ZY Ok CY Tzankov A Manyam GC Sun RF Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma Oncotarget 2015 6 23157 23180 26324762 PMC4695110
  119. [123]Ok CY Xu-Monette ZY Li L Manyam GC Montes-Moreno S Tzankov A Evaluation of NF-kappa B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions Mod Pathol 2015 28 1202 1213 26111978
  120. [124]Odqvist L Montes-Moreno S Sanchez-Pacheco RE Young KH Martin-Sanchez E Cereceda L NFkappaB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma Mod Pathol 2014 27 1331 1337 24603590
  121. [125]Aad G Abbott B Abdallah J Abdel Khalek S Abdelalim AA Abdesselam A Search for pair production of a new b′ quark that decays into a Z boson and a bottom quark with the ATLAS detector Phys Rev Lett 2012 109 071801 23006356
  122. [126]Curry CV Ewton AA Olsen RJ Logan BR Preti HA Liu YC Prognostic impact of C-REL expression in diffuse large B-cell lymphoma J Hematop 2009 2 20 26 19669219 PMC2713494
  123. [127]Eliopoulos AG Young LS LMP1 structure and signal transduction Semin Cancer Biol 2001 11 435 444 11669605
  124. [128]Izumi KM Kieff ED The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB Proc Natl Acad Sci U S A 1997 94 12592 12597 9356494 PMC25049
  125. [129]Mainou BA Everly DN Jr Raab-Traub N Unique signaling properties of CTAR1 in LMP1-mediated transformation J Virol 2007 81 9680 9692 17626074 PMC2045399
  126. [130]Fang W Zhang J Hong S Zhan J Chen N Qin T EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy Oncotarget 2014 5 12189 12202 25361008 PMC4322961
  127. [131]Karyampudi L Lamichhane P Krempski J Kalli KR Behrens MD Vargas DM PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-kappaB Cancer Res 2016 76 239 250 26567141 PMC4715980
  128. [132]Riley KJ Rabinowitz GS Yario TA Luna JM Darnell RB Steitz JA EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency EMBO J 2012 31 2207 2221 22473208 PMC3343464
  129. [133]Vento-Tormo R Rodriguez-Ubreva J Lisio LD Islam AB Urquiza JM Hernando H NF-kappaB directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus-mediated transformation of B-cells and in lymphomas Nucleic Acids Res 2014 42 11025 11039 25200074 PMC4176189
  130. [134]Qiu J Cosmopoulos K Pegtel M Hopmans E Murray P Middeldorp J A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia PLoS Pathog 2011 7 e1002193 21901094 PMC3161978
  131. [135]Kurokawa M Ghosh SK Ramos JC Mian AM Toomey NL Cabral L Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma Blood 2005 106 235 240 15790788 PMC1895122
  132. [136]Ishikawa C Mori N Epstein-Barr virus latent membrane protein 1 induces CD69 expression through activation of nuclear factor-kappaB Int J Oncol 2013 42 1786 1792 23546309
  133. [137]Faumont N Durand-Panteix S Schlee M Gromminger S Schuhmacher M Holzel M c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells J Virol 2009 83 5014 5027 19264782 PMC2682111
  134. [138]Montes-Moreno S Odqvist L Diaz-Perez JA Lopez AB de Villambrosia SG Mazorra F EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation Mod Pathol 2012 25 968 982 22538516
  135. [139]Ok CY Li L Xu-Monette ZY Visco C Tzankov A Manyam GC Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries Clin Cancer Res 2014 20 2338 2349 24583797 PMC4014309
  136. [140]Gebauer N Gebauer J Hardel TT Bernard V Biersack H Lehnert H Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly Leuk Lymphoma 2015 56 1100 1106 25030036
  137. [141]O'Connell RM Chaudhuri AA Rao DS Baltimore D Inositol phosphatase SHIP1 is a primary target of miR-155 Proc Natl Acad Sci U S A 2009 106 7113 7118 19359473 PMC2678424
  138. [142]Choy EY Siu KL Kok KH Lung RW Tsang CM To KF An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival J Exp Med 2008 205 2551 2560 18838543 PMC2571930
  139. [143]Martin-Perez D Vargiu P Montes-Moreno S Leon EA Rodriguez-Pinilla SM Lisio LD Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma Leukemia 2012 26 180 183 21788950
  140. [144]Perez-Rosado A Artiga M Vargiu P Sanchez-Aguilera A Alvarez-Barrientos A Piris M BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas J Pathol 2008 214 498 507 18189332
  141. [145]Dutton A Woodman CB Chukwuma MB Last JI Wei W Vockerodt M Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells Blood 2007 109 2597 2603 17148591
  142. [146]Nonaka M Horie R Itoh K Watanabe T Yamamoto N Yamaoka S Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts Oncogene 2005 24 3976 3986 15782119
  143. [147]Knecht H Berger C McQuain C Rothenberger S Bachmann E Martin J Latent membrane protein 1 associated signaling pathways are important in tumor cells of Epstein-Barr virus negative Hodgkin's disease Oncogene 1999 18 7161 7167 10597317
  144. [148]Schwarzer R Dorken B Jundt F Notch is an essential upstream regulator of NF-kappaB and is relevant for survival of Hodgkin and Reed-Sternberg cells Leukemia 2012 26 806 813 21946908
  145. [149]Mathas S Johrens K Joos S Lietz A Hummel F Janz M Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas Blood 2005 106 4287 4293 16123212
  146. [150]Amrein PC Attar EC Takvorian T Hochberg EP Ballen KK Leahy KM Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia Clin Cancer Res 2011 17 2977 2986 21402714 PMC3108904
  147. [151]Kater AP Spiering M Liu RD Doreen Te Raa G Slinger E Tonino SH Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study Leuk Res 2014 38 34 41 24238639
  148. [152]Morschhauser F Seymour JF Kluin-Nelemans HC Grigg A Wolf M Pfreundschuh M A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma Ann Oncol 2008 19 247 253 17906297
  149. [153]Schwartzberg L Hermann R Flinn I Flora D Hsi ED Hamid O Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma Br J Haematol 2014 166 91 97 24673609
  150. [154]Dunleavy K Pittaluga S Czuczman MS Dave SS Wright G Grant N Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Blood 2009 113 6069 6076 19380866 PMC2699229
  151. [155]Ruan J Martin P Furman RR Lee SM Cheung K Vose JM Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma J Clin Oncol 2011 29 690 697 21189393
  152. [156]Evens AM Smith MR Lossos IS Helenowski I Millenson M Winter JN Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study Br J Haematol 2014 166 514 520 24761968
  153. [157]Milhollen MA Traore T Adams-Duffy J Thomas MP Berger AJ Dang L MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma Blood 2010 116 1515 1523 20525923
  154. [158]Czuczman NM Barth MJ Gu J Neppalli V Mavis C Frys SE Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo Blood 2016 127 1128 1137 26675347 PMC4778163
  155. [159]Shah JJ Jakubowiak AJ O'Connor OA Orlowski RZ Harvey RD Smith MR Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma Clin Cancer Res 2016 22 34 43 26561559 PMC5694347
  156. [160]Rajan A Kelly RJ Trepel JB Kim YS Alarcon SV Kummar S A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas Clin Cancer Res 2011 17 6831 6839 21908572 PMC3207004
  157. [161]Yong K Cavet J Johnson P Morgan G Williams C Nakashima D Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies Br J Cancer 2016 114 7 13 26695442 PMC4716540
  158. [162]Roue G Perez-Galan P Mozos A Lopez-Guerra M Xargay-Torrent S Rosich L The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78 Blood 2011 117 1270 1279 21106982
  159. [163]Kaufman KL Jenkins Y Alomari M Mirzaei M Best OG Pascovici D The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia Oncotarget 2015 6 40981 40997 26556860 PMC4747384
  160. [164]Friedberg JW Sharman J Sweetenham J Johnston PB Vose JM Lacasce A Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 2010 115 2578 2585 19965662 PMC2852362
  161. [165]Flinn IW Bartlett NL Blum KA Ardeshna KM LaCasce AS Flowers CR A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Eur J Cancer 2015 54 11 17 26707592
  162. [166]Chanan-Khan A Cramer P Demirkan F Fraser G Silva RS Grosicki S Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study Lancet Oncol 2016 17 200 211 26655421
  163. [169]Byrd JC Harrington B O'Brien S Jones JA Schuh A Devereux S Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia N Engl J Med 2016 374 323 332 26641137 PMC4862586

Cited by

Sorted by citations

Authors
Yu, L., Li, L., Medeiros, L. J., & Young, K. H.
Affiliations
  • First Affiliated Hospital of Zhengzhou University (CN)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Young, Ken H.
ORCID
Venue
Blood Reviews
Publisher
Elsevier BV
Published
2017-03
Volume
31
Issue
2
Pages
77-92
ISSN
0268-960X (ISSN-L)
DOI
10.1016/j.blre.2016.10.001
PMC
PMC5382109
OpenAlex
W2531430052
Cited by
105
References
7
Citations by year
2026: 9 · 2025: 9 · 2024: 10 · 2023: 11 · 2022: 10 · 2021: 7 · 2020: 10 · 2019: 17 · 2018: 13 · 2017: 8 · 2016: 1
FWCI
1.18
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Blood Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R01CA187415, RC1CA146299, P50CA142509, R01CA138688, P50CA136411, P30CA016672)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
NF-κB signaling, lymphoid malignancies, lymphoma, NF-κB inhibitors, treatment resistance, apoptosis, anti-apoptotic pathways, tumor microenvironment, combination therapy, clinical trials, oncogenic signaling
MeSH terms
Animals, Antineoplastic Agents, Clinical Trials as Topic, Humans, Leukemia, Lymphoid, Lymphoid Tissue, Lymphoma, Mutation, Biomarkers, Tumor, Signal Transduction, Gene Expression Regulation, Neoplastic, NF-kappa B, Treatment Outcome, Molecular Targeted Therapy, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review